We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Worldwide Scare Following Unearthing of Defective Breast Implants

By HospiMedica International staff writers
Posted on 12 Jan 2012
Accusations against silicone implant manufacturer Poly Implant Prothese (PIP; La Seyne-sur-Mer, France) has triggered widespread panic in several countries, including France, Israel, Sweden, and the Czech Republic, which have advised thousands of women to have the implants removed.

The company produced around 100,000 implants per year, during almost 20 years of production, and approximately 300,000 women worldwide have had silicone gel-implant products implanted to enhance breast size or repair lost tissue. More...
The implants have been exported to Latin American countries such as Brazil and Argentina, Western European markets including Britain, Germany, Spain and Italy, as well as Australia, and almost 60 other countries worldwide. The company went into liquidation in 2011 following the erupting public-health care scandal by order of the French government.

RTL radio (Paris, France) has said it has obtained an exact breakdown of the materials used in the faulty implants, including Baysilone, Silopren, and Rhodorsil, all of which are industrial products never tested or approved for clinical use. The products, used in the oil or rubber industries, allegedly contributed to the silicone gel implants having a high rupture rate. Authorities already knew that the implants contained industrial rather than medical quality silicone, but it has been further revealed that the company also used petroleum industry additives as early as 2005.

“We're facing a health crisis, linked to a fraud,” said leading French plastic surgeon Laurent Lantieri, MD, who is serving on the French advisory committee investigating the crisis that recommended the unprecedented step of ordering the removal of every PIP implant in France. “There's no urgency, but we have no choice. All these implants have to be removed.”

Interpol (Lyon, France) has issued a red notice seeking the arrest of Jean-Claude Mas (72), the founder of the PIP breast implant company, who is listed as being sought in Costa Rica for offences concerning “life and health.” According to confidential documents, a second company, France Implant Technologie (FIT), was registered in June 2011 to Nicolas Lucciardi, 27, and his 24-year-old sister Peggy, the children of Dominique Lucciardi, Mas' former partner. Mas himself was appointed as a technical and commercial consultant to the new company, which intended to produce 400 silicone gel implants per day at the former PIP production site in the south-east of France.

Related Links:
RTL
Interpol




Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Ultrasound System
FUTUS LE
Pulmonary Ventilator
OXYMAG
X-Ray System
Leonardo DR mini III
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.